Gufic Biosciences FY26 Consolidated Revenue at ₹94,047 Crore; Recommends 10% Dividend
Gufic Biosciences reported audited consolidated revenue of ₹94,047.54 crore and a net profit of ₹6,314.87 lakh for FY26. The company recommended a final dividend of ₹0.10 per share (10%) for FY26, pending shareholder approval at the AGM.
The announcement includes audited financial results for the full year and a dividend recommendation, which are material information for investors.
The company reported strong financial results with significant revenue and recommended a dividend, indicating positive performance.
Gufic Biosciences Limited announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board of Directors, in a meeting held on May 29, 2026, approved these results.
For the financial year ended March 31, 2026, the consolidated revenue from operations stood at ₹94,047.54 crore. The consolidated net profit for the period was ₹6,314.87 lakh. The standalone revenue from operations was ₹25,205.23 crore for the quarter and ₹94,047.54 crore for the year. The standalone net profit for the quarter was ₹2,057.44 lakh and ₹6,314.87 lakh for the year.
The Board of Directors has recommended a final dividend of ₹0.10 per equity share (10%) for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting.
The company's statutory auditors, Mittal Agarwal & Co., have issued an audit report with an unmodified opinion on the financial results.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.